EXAS vs TGTX · rev $2.76B vs P/E 18, rev $240.3M
EXACT Sciences Corporation (EXAS) versus TG Therapeutics Inc (TGTX) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported TGTX revenue for 2026-06-30 was $240.3M. Net income was $7.8M. Revenue was up 17.3% from 2026-03-31 to 2026-06-30. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
EXAS currently screens at market cap $20.03B. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
Not investment advice. Open the EXAS and TGTX stock pages for the full models.
Not investment advice.